Endocrine Abstracts

Background: Graves’ disease (GD) is an autoimmune disease caused by autoantibody targeting the thyrotropin receptor (TSHR) in the thyroid gland, resulting in hyperthyroidism with an annual incidence of 15 to 80/100,000 people worldwide. Current mainstream treatments for GD include aggressive treatment with radioiodine and thyroidectomy or unspecific immune-modulating therapy with glucocorticoids, antithyroid medications or anti-CD20 antibodies like Rituximab. Therefore, o...